TNFAIP3 and systemic inflammatory response syndrome: This effect may be mediated by changes in NF-κB activity caused by variable expression of TNFAIP3. Our finding could be of value in evaluation of the risk of developing SIRS in AP patients, and could eventually lead to individualized targeted treatment in AP patients, based on genetic background.